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Population and methods: we analysed 110 episodes of CAP or AECB in 107 pts in our unit from l/Dee/98 to 30/O&99; we 
evaluated antibiotic treatment before and during hospitalization, sputum isolates and serology, mean hospital stay. 
Results: CAP and AECB represented respectively 28% and 61% of the episodes; mean age was 63221~ (16-92y) and 70&9y 
(43-93y) in the 2nd group. Mean hospitalization was 20? 11 d (845d) for CAP and 19+ 12 d (3-75d) for AECB episodes. 71% 
of patients with CAP and 45% of those with AECB had received antibiotic treatment in the 3 days before admission. 43% of 
the patients with CAP received more than one drug; drugs including penicillins (P), cephalosporins (C), fluoroquinolones 
(FQ), macrolides (M). FQ were most frequently used for AECB, followed by C,M,P In 42% of CAP, no germs were isolated 
and in 29% of the cases multiple agents were identified. Similarly no pathogen was identified in 53% of AECB. 
Conclusions: an increased hospital stay in both CAP and AECB episodes was observed compared to mean national values, 
possibly related to patients’ demographics. Relevant differences in ethiology of CAP and AECB were observed compared to 
available reports at other sites, with no recorded case of Pen R S. Pneumoniae. These data further confirm that local 
guidelines and hospital formularies should take into account both clinical and microbiological surveys. 
10. Clinical efficacy and safety of clarithromycin in the initial treatment of community 
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Aim: to evaluate efficacy and safety of clarithromycin in the initial treatment of community-acquired pneumonia (CAP) in a 
prospective, noncomparative, multicentre clinical trial. 
Patients and methods: 87 outpatients with symptoms and radiologically confirmed pneumonia were included. We evaluated 
clinical symptoms at the beginning of the treatment, after three days and after the end of the treatment. Chest x-ray and 
laboratory findings including C-reactive protein (CRP) were evaluated at the beginning and not later than 9 days after the end 
of the treatment. Patients received 500 mg of clarithromycin twice daily. 
Results: Duration of treatment was 5 to 14 days (mean 1223 days). Complete radiological resolution was achieved in 72 
patients (85%). Chest pain was present in 67% before and 6% after the treatment, productive cough in 54% vs. 13%, non- 
productive cough in 46% vs. 17%, purulent sputum in 22% vs. O%, muco-purulent sputum in 28% vs. 6%, dyspnea in 54% vs. 
1 l%, chills in 55% vs. l%, pathological physical chest examination in 86% vs. 5%. Mean CRP was 53.0239.9 (SD) mg/l before 
and 11.3? 14.9 (SD) mg/l after the treatment. 97% of patients (84187) were successfully treated (cure or improvement). In 2 
out of 3 failures patients did not complete the treatment due to adverse reactions. 16% (14/87) of all patients experienced 
adverse reactions; most common were transient gastrointestinal symptoms. 
Conclusions: Initial treatment with clarithromycin was highly effective in mild to moderate CAP in adults, and was associated 
with an acceptable incidence of adverse reactions. 
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Objective. The purpose of this study was to determine the effect of age, severity of lung disease, severity and frequency of 
exacerbation, steroid use, choice of an antibiotic and the presence of comorbidity on the outcome of treatment for an acute 
exacerbation of chronic obstructive lung disease (COPD). 
Methods. A retrospective chart analysis was conducted in 107 outpatients with COPD who were treated with an antibiotic for 
an acute exacerbation of COPD over 24 months. Severity of an acute exacerbation was defined using Anthonisen’s criteria of 
increased dyspnea, increased sputum volume and increased sputum purulence. Severity of lung disease was stratified based on 
FEVi% predicted using ATS guidelines (Stage I - FEVl 50%; Stage II - FEVi 35% to 49%; Stage III ~ FEVi ~35%). 
Treatment outcome was judged successful when the patient had no return visit in four weeks for a respiratory problem. Failure 
was defined as a return visit in four weeks for persistent respiratory symptoms that required a change of an antibiotic. 
Results. One-hundred and seven patients with COPD (mean age&SD 66.9k9.5 years) experienced 232 exacerbations over 24 
months. First-line antibiotics (trimethoprim-sulfamethoxazole, ampicillinlamoxicillin and erythromycin) were used to treat 
78% of all exacerbations. Treatment failure was noted in 12.1% of first exacerbations and 14.7% of all exacerbations, with 
more than half the failures requiring hospitalization Host factors that were independently associated with treatment failure 
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included: FEVl ~35% (46.4% vs. 22.4%; P=O.O47), use of home oxygen (60.7% vs. 156%; P<O.OOOl), frequency of 
exacerbation (3.822.0 vs. 1.6r0.91; P<O.OOl), history of previous pneumonia (64.3% vs. 35.1%; P<O.O07), history of sinusitis 
(28.6% vs. 88%; P<O.O09) and use of maintenance steroids (32.1% vs. 15.2%; P=O.O52). Using stepwise logistic regression 
analysis to identify the top independent variables, the use of home oxygen (P=O.O002) and frequency of exacerbation 
(P<O.OOOl) correctly classified failures in 83.3% of the patients. Surprisingly, age, the choice of an antibiotic and the presence 
of any one or more comorbidity did not affect the treatment outcome. 
Conclusion. The results of our study suggest that patient host factors and not antibiotic choice may determine treatment 
outcome. Prospective studies in appropriately stratified patients are needed to validate these findings. 
Study partly supported by a research grant from Bayer Pharmaceuticals, Inc. Data also presented previously at American 
College of Chest Physicians in Toronto, Canada, November 10, 1998. 
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Background: Lower respiratory tract infections are often the cause of acute excarbations, and the treatment of infection is an 
important part of therapy of COPD. 
Objective: To compare the effects of erythromycin with other routinly prescribed antibiotics in patients with acute purulent 
exacerbations of COPD. 
Methods: Eighty-two patients with acute purulent exacerbation of COPD were randomized to receive either a course of orally 
administered antibiotic therapy with erythromycin 500 mg every 6 h for 10 days (n=42), or a standard course of oral 
antibiotics (doxycycline100 mg every 12 h for 10 days or cefaclor 500 mg every 8 h for 10 days) (n=40). The two groups of 
patients were comparable in their clinical and spirometric profiles. 
Results: In the erythromycin group spirometric values, PEFR scores, symptom scores and physician global evaluations were 
statistically significantly better (P<O.OOl) compared with control group. In both groups treatment was well tolerated, with 
similar incidence of side effects. 
Conclusion: Erythromycin is effective and appropriate antibiotic for the treatment of acute bacterial exacerbations in patients 
with COPD. 
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Four different bacterial sampling chambers containing Mueller Hinton culture medium in Petri dishes have been compared 
for demonstrating the best results using the same portable aerodispersed particles sampler (PARTRAP FA 52) with aspiration 
flow of 10 liters per minute, equivalent to Current Volume of adult respiratory flow at rest. Twenty environmental 
aerobiological samplings were performed per 30 minutes with each different chamber in the same environment (Pneumonology 
Service). The cylindrical chambers made in aluminium differed essentially in the varying diameter of the punctured surface 
which allowed air passage and a diverse impact of the air column on the surface of the 7.5 cm diameter Petri dishes. Differing 
diaphragm diameter applied at the opening of the sampler chamber causes a different spatial distribution of bacterial growth. 
Optimal bacterial growth expressed in Colony Forming Units (CFU) and in regular distribution on the Petri dish surface was 
obtained with a type of sampling chamber with a central punctured diaphragm of 5 cm diameter, in this case all the bacterial 
colonies were well identified as a ‘stars in the sky’, in the other chambers the growth was present respectively in the central 
part of the Petri dish, or in periphery with high Colony Forming Units (CFU) concentration and sometimes it was impossible 
to determine it correctly. A portable, light (approximately 500 g.), low cost aerodispersed particle sampler apparatus may be 
useful in sampling bacterial and/or mould particles directly on Petri dishes for great practical importance in the determination 
of hygienic conditions of the sanitary environment. 
